A very aggressive disease with a poor prognosis, gallbladder cancer may be connected to higher exposure to estrogens, according to a group of researchers at the University of Houston (UH).
Dr. Jan-Ĺke Gustafsson, Robert A. Welch Professor in UH's biology and biochemistry department, described his team's findings in a paper titled "Estrogen-dependent gallbladder carcinogenesis in LXRβ-/- female mice" appearing in a recent issue of the journal Proceedings of the National Academy of Sciences, one of the world's most-cited multidisciplinary scientific serials.
"For the first time, we show in this paper that the absence of liver X beta receptors, or LXRβ, in a complex interplay with estrogens, induces gallbladder cancer exclusively in female mice," Gustafsson said. "Interestingly, the elimination of estrogens prevents the development of tumors in this animal model."
In the study, the team found that chronic inflammatory gall bladder disease characteristic of LXRβ-/- mice, led to gallbladder lesions that developed and evolved into cancer in older female mice. It is known that metabolic and hormonal alterations have been associated with this invasive disease, and LXRβ is a sensor for cholesterol derivatives. By removing the ovaries and reducing estrogen levels, the researchers were able to prevent the development of tumors in LXRβ-/- mice.
There are many crucial clinical implications resulting from these findings. First, drugs that decrease the level of estrogens might be added to the conventional treatment of gallbladder cancer. And, in the long term, pharmacological activators of LXRβ could become potential new anti-cancer drugs that may reduce or regulate the proliferation of gallbladder cells.
Additionally, in looking at families affected by hereditary gallbladder cancers, this research could shed light upon mutations in the sequence of LXRβ that may be responsible for this particular cancer, indicating a higher risk for this disease. This, in turn, could one day be used to determine individual risks.
"Going forward, we need to estimate exactly the levels of LXRβ and its activators in human gallbladder cancers, particularly in female patients," Gustafsson said. "Once the presence and the function of LXRβ in the human gallbladder are clear, we are going to test the potential effects of LXRβ molecules on human gallbladder cancer cells."
In addition to Gustafsson, the UH team on this project consists of post-doctoral students Drs. Chiara Gabbi, who made the discovery, Hyun-Jin Kim and Rodrigo Barros, as well as biology and biochemistry professor Margaret Warner, who has worked with the Gustafsson group since 1986. Marion Korach-Andre' from the Center for Biosciences at the Karolinska Institute in Sweden also contributed to this study.
Explore further: Second-line cetuximab active beyond progression in quadruple wild-type patients with mCRC